Triglyceride-rich lipoproteins in chronic kidney disease patients undergoing maintenance haemodialysis treatment

International Journal of Clinical Practice

Volumn 66, Issue 4, 2012, Pages 394-398

  Homma, K ^a,b   Homma, Y ^a,c   Yamaguchi, S ^b   Shiina, Y ^c   Wakino, S ^b   Hayashi, K ^b   Hori, S ^b   Itoh, H ^b  

^a Hiratsuka Lifestyle Related Diseases and Hemodialysis Clinic   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REMNANT LIKE PARTICLE CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; ATHEROGENESIS; BLOOD ANALYSIS; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; HEMODIALYSIS; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOASSAY; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY;

AGED; APOLIPOPROTEINS; CASE-CONTROL STUDIES; CHOLESTEROL; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE, CHRONIC; LIPID METABOLISM; LIPOPROTEINS; MALE; MIDDLE AGED; RENAL DIALYSIS; TRIGLYCERIDES;

EID: 84859095228     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02862.x     Document Type: Article

References (22)

1. Havel RJ, Kane JP,. Introduction: structure and metabolism of plasma lipoproteins. In:, Scriver SPR, Beaudet AL, Sly WS, Valle DV, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: Mcgraw-Hill, 2001: 2705-2716.
2. Campos E, Nakajima K, Tanaka A, Havel RJ,. Properties of an apoprote4in E-enriched fraction of triglyceride-rich lipoprotein isolated from huma plasma with a monoclonal antibody to apo B-100. J Lipid Res 1992; 33: 369-380.
3. Campos E, Kotite L, Blanche P, et al., Properties of triglyceride-rich and cholesterol rich lipoproteins in the remnant-like particle fraction of human blood plasma. J Lipid Res 2002; 43: 365-374. (Pubitemid 34252266)
4. Trickler TB, Dallinga-Tie GM, Cohn JD, Chapman MJ,. Elevated remnant-like particle cholesterol consentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation 2004; 109: 1918-1925. (Pubitemid 38544478)
5. Nakajima K, Nakano T, Tanaka A,. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidixed LDL and remnant lipoproteins in plasma. Clin Chim Acta 2006; 367: 36-47.
6. Appel G,. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169-183.
7. Neatel PJ, Fidge NH, Tan MH,. Increased lipoprotein-remnant formation in chronic renal failure. New Engl J Med 1982; 307: 329-333. (Pubitemid 12082192)
8. Ron D, Oren I, Aviram M, Better OS, Brook JG,. Accumulation of lipopprotein remnants in patients with chronic renal failure. Atherosclerosis 1983; 46: 67-75. (Pubitemid 13180786)
9. Oda H, Yorioka N, Nishida Y, Kushihara S, Ito T, Yamakido M,. Remnant-like particle cholesterol may indivcate atherogenic risk in patients on chronic hemodialysis. Nephron 1997; 76: 7-14. (Pubitemid 27199032)
10. Hayashi T, Hirano T, Taira T, et al., Remarkable increase of apolipoprotein B-48 level in diabetic patients with end-stage renal disease. Atherosclerosis 2008; 197: 154-158. (Pubitemid 351273234)
11. Brunzell JD, Deeb SS,. Familial lipoprotein lipase deficiency, apo C-II deficiency, and hepatic lipase deficiency. In:, Scriver SPR, Beaudet AL, Sly WS, Valle DV, eds. The Metabolic and Molecular Bases of Inherited disease, 8th edn. New York: Mcgraw-Hill, 2001: 8.
12. Nakamura M, Taniguchi Y, Yamamoto K, Hino K, Manabe M,. Homogeneous assay of serum LDL-cholesterol on an automated analyzer. Clin Chem 1997; 43: S260-S261.
13. Noma A, Hata Y, Goto Y,. Quantification of serum apolipoprotein A-I, A-II, B, C-II, C-III, and E by turbidimetric immunoassay: reference values, age-, sex-related differences. Clin Chim Acta 1993; 221: 147-157.
14. Nakajima K, Saito T, Tamura A, et al., Cholesterol in remnant-like lipoproteins in human serum using monoclonal antiapo B-100 and antiapo A-I immunoaffinity mixed gel. Clin Chim Acta 1993; 223: 53-71. (Pubitemid 24050910)
15. Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
16. Homma Y,. Predictors of atherosclerosis. J Atheroscler Thromb 2004; 53: 79-88.
17. Chan MK, Persaud J, Varghese Z, Moorhead JF,. Pathogenic role of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int 1984; 25: 812-818. (Pubitemid 14082188)
18. Mekki K, Prost J, Bouchenak M, Remaoun M, Belleville J,. Plasma lipoprotein lipase, hepatic lipase activities, VLDL, LDL compositions at different times of hemodialysis. Atherosclerosis 2003; 169: 269-277. (Pubitemid 37297473)
19. Nishiwaki M, Ishikawa T, Homma Y, et al., Effects of pravastatin on plasma lipids, apolipoproteins, Lp(a), remnant-like particle, cholesteryl ester transfer protein, and lecithin: cholesterol acyltransferase: 12-month study. Nutr Met Cardiovasc Dis 1994; 4: 10-15.
20. Strippoli G, Navaneethan S, Johnson DW, et al., Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials. Br Med J 2008; 336: 645-651. (Pubitemid 351481234)
21. de Sauvage Nolting PR, Twickler MB, Dallinga-Thie GM, et al., Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin treatment. Circulation 2002; 106: 788-792.
22. Homma Y, Michishita I, Hayashi H, et al. Effects of low-dose simvastatin on the distribution of plasma cholesterol and oxidized low-density lipoprotein in three ultracentrifugally separated low-density lipoprotein subfractions: 12 month, open-label trial. J Athroscler Thromb 2010; 17: 1049-1053.